This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




  Mobile version    RSS    Subscribe    Unsubscribe    Archive    Media Kit Aug. 2, 2012

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us  


 


Report of a consensus conference on transplant program quality and surveillance
American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Public reports of organ transplant program outcomes by the U.S. Scientific Registry of Transplant Recipients have been both groundbreaking and controversial. The reports are used by regulatory agencies, private insurance providers, transplant centers and patients. Failure to adequately adjust outcomes for risk may cause programs to avoid performing transplants involving suitable but high-risk candidates and donors. At a consensus conference of stakeholders held Feb. 13–15, the participants recommended that program-specific reports be better designed to address the needs of all users. More



 SOCIETY NEWS


Campath Distribution change
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Please see the following information regarding Sanofi Oncology's notice of the changing distribution model for Campath (alemtuzumab). This program will be put in place on Sept. 4. Sanofi Oncology is committed to ensuring that patients who need Campath will receive it and Sanofi will provide the product free of charge through the Campath Distribution Program.

Need a reason to visit the beautiful south of France? Come to the ESOT AST Joint Meeting!
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Join us Oct. 12-14 in Nice, France, to witness cutting edge science presented by an international pool of expert speakers. Click here for a personal invitation and more information. Hope to see you there!

Make the most of your AST membership — join a community of practice
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Participation in AST's communities of practice can enhance your member experience. The AST has 12 unique communities of practice which serve our member constituencies. Each community provides the opportunity for AST members to work together to educate one another and others on specific areas of transplantation, and also serves as a forum for transplant professionals to discuss common problems and issues that affect the community. The AST's communities of practice are an integral component of the society, providing networking and leadership opportunities for AST members, and guiding and supporting larger association-wide initiatives. For a full list of all AST communities of practice and for more information, click here.

Save the date
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article

Antibody Mediated Rejection in Liver Transplantation
Endorsed by the American Society of Transplantation
March 22-23, 2013, Dallas







 TRANSPLANT NEWS


2 more patients HIV-free after bone marrow transplants
ABC News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Researchers at Brigham and Women's Hospital in Boston have discovered that, following bone marrow transplants, two men no longer have detectable HIV in their blood cells. The finding is significant because it suggests that by giving these patients transplants while they were on anti-retroviral therapy, they may have been cured of the AIDS-causing virus.

Related articles:
  • Bone marrow transplant eliminates signs of HIV infection (HealthCanal.com)
  • HIV undetectable in 2 men after bone marrow transplants (U.S. News & World Report)
  • Bone marrow transplant eliminates HIV traces from 2 patients' DNA: Call it a cure? (CBS News)
  • More

    Sirolimus has anti-skin cancer effect in kidney transplant patients
    News-medical.net    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Switching from calcineurin inhibitors (tacrolimus and cyclosporin) to a sirolimus-containing immunosuppression regimen may help reduce the incidence of secondary skin cancer after kidney transplantation, suggests research published in The New England Journal of Medicine. Patients receiving kidney transplants are known to have high risk for skin cancer after transplantation, which is thought to be largely due to the immunosuppressive therapy they are required to take to prevent rejection.

    Related articles:
  • Drug cut skin cancers after transplant (MedPage Today)
  • Immunosuppressant switch cuts skin cancer post-transplant (Medical Xpress)
  • More

    Long-term dialysis boosts cancer risk after renal transplantation
    Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Patients on long-term dialysis prior to receiving a donor kidney increases their risk for cancer following transplantation, according to findings presented at the 24th International Congress of The Transplantation Society. In a study of 5,417 patients, researchers led by Dr. Germaine Wong, MBBS, a nephrologist and early career research fellow at the University of Sydney's School of Public Health in Australia, found that patients on dialysis for more than 4.5 years had a greater than threefold increased risk for lung cancer compared with those who had dialyzed for fewer than 1.5 years. They also had a 2.5 times increased risk for urinary tract cancer. More

    Human Papillomavirus-associated cancers — United States, 2004-2008
    Center for Disease Control and Prevention    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Human papillomavirus–associated malignancies occur more commonly in immunosuppressed hosts, including transplant recipients. This report highlights the current trends in HPV-associated malignancies in the United States. More

    University of Miami cell transplant research on spinal cord patients gets FDA approval
    Sun Sentinel    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    The Miami Project to Cure Paralysis has received federal approval to begin a groundbreaking clinical trial studying the effects of human cell transplants on people with spinal cord injuries. The center's leading researchers made the announcement in what they hope will be a first step in curing paralysis — and perhaps lead to medical advancements that could someday treat neurological conditions such as Alzheimer's or Parkinson's disease. More

    Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients
    American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Voriconazole is commonly used for prophylaxis and treatment of invasive aspergillosis in lung transplant recipients. However, the use of voriconazole may at times be limited by the development of hepatotoxicity. The five risk factors identified in a univariate analysis were used to build a K-nearest neighbor algorithm predictive model for hepatotoxicity. More

    Babesiosis surveillance — 18 States, 2011
    Centers for Disease Control and Prevention    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    For the first time, U.S. cases of babesiosis were reported using a standard national case definition. In 2011, a total of 1,124 cases of babesiosis were reported. Over half (57 percent) of the cases were in persons over 60 years of age and 97 percent of cases were reported by seven states. More

    High BMI raises wound complication risk in transplant patients
    Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Kidney transplant recipients with a high body mass index have a greater risk of wound complications, researchers concluded. In a retrospective study of 508 adult kidney transplant recipients, Dr. Stephanie Zrim, Flinders University in Adelaide, Australia, and colleagues found that wound complications occurred in 3 percent of patients with a BMI (in kg/m2) of 18.5-24.9 (normal weight), 8 percent of patients with a BMI of 25-29.9 (overweight) and 13 percent of those with a BMI of 30 or higher (obese), according to findings published in Nephrology. More
     



    AST eNews

    Colby Horton, Vice President of Publishing, 469.420.2601
    Download media kit

    Courtney Hodges, Content Editor, 972.402.2604   
    Contribute news


    This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

    Recent issues
    July 26, 2012
    July 19, 2012
    July 12, 2012
    July 5, 2012






    7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063